After Acquiring A Competitor, TopoTarget Secures $19.8M Series C

Following the all-stock acquisition of competitor G2M Cancer Drugs AG on March
1, Danish oncology start-up TopoTarget said it has secured EUR15 million ($19.8
million) of Series C financing.